CD19 and neoplasm: A recent study by Park and colleagues has used an oncolytic vaccinia virus equipped with the nucleotide sequence of a truncated form of CD19 (truncCD19OV) to infect tumor cells for the surface expression of truncCD19 enabling their targeting with CD19-redirected CAR-Ts (113).